Aclaris Therapeutics, Inc. (ACRS) Could Burn Your Portfolio. The Stock Formed Wedge Down Chart Pattern

December 7, 2017 - By Maria Brooks

The stock of Aclaris Therapeutics, Inc. (ACRS) formed a down wedge with $21.45 target or 3.00 % below today’s $22.11 share price. The 6 months wedge indicates high risk for the $681.76M company. If the $21.45 price target is reached, the company will be worth $20.45M less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock increased 0.41% or $0.09 during the last trading session, reaching $22.11. About 268,087 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has risen 25.57% since December 8, 2016 and is uptrending. It has outperformed by 8.87% the S&P500.

Analysts await Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings on March, 21. They expect $-0.90 EPS, down 83.67 % or $0.41 from last year’s $-0.49 per share. After $-0.63 actual EPS reported by Aclaris Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 42.86 % negative EPS growth.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ratings Coverage

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Monday, November 2 by Jefferies. The company was maintained on Wednesday, August 9 by Cantor Fitzgerald. The firm has “Buy” rating given on Friday, July 28 by Jefferies. As per Monday, November 2, the company rating was initiated by Citigroup. The stock has “Buy” rating by Jefferies on Thursday, August 31. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Outperform” rating given on Monday, November 2 by William Blair. JMP Securities initiated Aclaris Therapeutics, Inc. (NASDAQ:ACRS) on Friday, September 30 with “Market Perform” rating. Jefferies maintained Aclaris Therapeutics, Inc. (NASDAQ:ACRS) on Monday, September 19 with “Buy” rating. The firm has “Outperform” rating by Leerink Swann given on Tuesday, November 29. Jefferies maintained the shares of ACRS in report on Friday, August 12 with “Buy” rating.

More notable recent Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news were published by: Globenewswire.com which released: “Aclaris Therapeutics to Announce Third Quarter 2017 Financial Results on …” on October 31, 2017, also Globenewswire.com with their article: “Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly” published on November 09, 2017, Seekingalpha.com published: “Aclaris Therapeutics’ (ACRS) CEO Dr. Neal Walker on Q2 2017 Results – Earnings …” on August 11, 2017. More interesting news about Aclaris Therapeutics, Inc. (NASDAQ:ACRS) were released by: Globenewswire.com and their article: “Aclaris Therapeutics Presents New Data at American College of Rheumatology …” published on November 21, 2017 as well as Globenewswire.com‘s news article titled: “Aclaris Therapeutics Submits Marketing Authorization Application in Europe for …” with publication date: August 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.